CRAD B C-RAD AB

Stockholm Patent and Market court resolution of dispute over C-RAD’s claim for Beamocular patent

Stockholm Patent and Market court resolution of dispute over C-RAD’s claim for Beamocular patent

The Stockholm Patent and Market court confirmed C-RAD’s entitlement to the patent application “Ionizing radiation detecting device” in its verdict published today. C-RAD filed a patent entitlement lawsuit in May 2017 against the company Beamocular AB.

A patent application for an invention was filed by Beamocular on March 2, 2015, followed by a PCT patent application on March 2, 2016. The founder and CEO of Beamocular, Kristofer Maad was previously employed by C-Rad as the CEO of C-RAD Imaging AB until September 2014.

C-RAD Imaging AB is a subsidiary of C-RAD focused on the development of a portal imaging and dosimetry device. The disputed invention is related to the research and development for C-RAD’s imaging detector for which C-RAD Imaging has filed its own earlier patent application in 2013, which now is a granted US patent. The detector has not been commercialized yet.

The company Beamocular filed for bankruptcy in the meantime. Beamocular still has the right to file an appeal.

C-RAD had legal and associated costs of approximately 1,5 MSEK related to the lawsuit, whereas the largest part has already been accounted for as cost until the first quarter 2019. As C-RAD prevailed in this dispute C-RAD shall be reimbursed by Beamocular for the full cost. Due to the financial situation of Beamocular, C-RAD might not get reimbursed in full.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit -rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone , Email

This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 13:00 CET on July 26, 2019.

Attachment

EN
26/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C-RAD AB

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Erik Cassel
  • Erik Cassel

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

Erik Cassel
  • Erik Cassel

Sector Fast Comment - Hospital data update

Better hospital margins in August Congress passed supportive spending bill Small positive for companies with capex exposure

Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke

C-RAD AB - Record heat on orders beat

Remarkable order intake 35% better than ABGSCe ‘23e EBIT up 8% and ‘24e up 4% Fair value range of SEK 45-95/share

ResearchPool Subscriptions

Get the most out of your insights

Get in touch